A quarterly publication of myeloma research from our medical editors

The IMF’s quarterly journal features scientific and clinical news and stories about education and awareness programs, patient meetings, and advocacy activities. Available online and by mail.

Do you want to read about the latest myeloma research, vetted by the IMF's Medical Editors? Also learn about worldwide events in the myeloma research community and gain inspiration from IMF donors and fundraisers. You can with the Myeloma Today!

The IMF’s quarterly journal features

  • scientific and clinical news
  • reports from international medical meetings, such as ASCO and ASH
  • stories about educational outreach
  • pictures and summaries of our annual Myeloma Action Month initiative
  • information about advocacy initiatives and how you can get involved
  • the latest news from international and U.S.-based patient meetings
  • inspirational tales from patients, caregivers, donors, fundraisers, and more!
Highlights include reports from the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) and the 2019 Summit of the International Myeloma Working Group (IMWG).
Highlights include scientific news on CAR T-cell therapies in myeloma and the Joint Honorary Doctorate in Recognition of Scientific Excellence received by Susie Durie and Dr. Brian G.M. Durie.
Highlights include research news from the 2018 American Society of Hematology (ASH) Annual Conference, the iStopMM initiative, and FDA approvals and cautions about immunotherapies in myeloma.
The Fall 2018 Myeloma Today covers the ASCENT trial, Blood Cancer Awareness Month, the IMF Comedy Celebration, and more.
Myeloma Today is a multiple myeloma journal featuring clinical news, patient stories, education, awareness and advocacy articles. Online and print.
The Summer 2018 Myeloma Today covers medical meetings (ASCO 2018, IMWG Summit 2018, ONS 2018), and more. Online and print.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.